Health experts seek ways to eliminate malariainfectious disease Infectious disease
A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. that kills around 900,000 people every year.
Key among the strategies for the fifth Multilateral Initiative on Malaria is the development of an effective anti-malaria vaccine, a project scientists have been researching since the late 80s.
The experts were to launch later Tuesday a status report on the Phase 3 trials of the vaccine known as RTS (Request To Send) An RS-232 signal sent from the transmitting station to the receiving station requesting permission to transmit. Contrast with CTS.
1. (operating system) RTS - run-time system.
2. ,S targeted to be at least 50 percent effective against the severe form of malaria and to last up to one year.
The RTS,S is the most clinically advanced malaria vaccine Malaria vaccines are an area of intensive research, however, no effective vaccine has yet been introduced into clinical practice. Justification for malaria vaccine research so far, according to according to
1. As stated or indicated by; on the authority of: according to historians.
2. In keeping with: according to instructions.
3. the Malaria Vaccine Initiative (MVI MVI Multivitamin
MVI Multi-Vendor Import
MVI Melt-Volume Index
MVI Motor Vehicle Incident
MVI MODIS Vegetation Index
MVI Multiple Variable Inversion
MVI Microsoft Virus Initiative
MVI Multi-Vitamin Injection
MVI Motion Video Instructions ).
Results of Phase 2 trials, which were announced last year, showed 53 percent efficacy against clinical malaria in young children.
"History has shown us that a vaccine would add a powerful, cost-effective way to save lives and help eliminate this disease," MVI's director Christian Loucq said in a statement Monday.
Clinical trials for the third phase are being carried out in seven African countries and will involve up to 16,000 children aged between six weeks to 17 months.
The third phase monitors safety and potential side effects Side effects
Effects of a proposed project on other parts of the firm. and evaluates efficacy on a large scale.
If successful, the phase three testing and license of the vaccine would make it a "first generation malaria vaccine that is at least 50 percent effective against severe disease and death and lasts more than one year," MVI said.
The vaccine is primarily intended for infants and children under five who are the most vulnerable to malaria.
In 2006, the international community set a long-term goal of having by 2025 a malaria vaccine that would be at least 80 percent effective against the less severe forms of the disease and last longer than four years.
Other strategies include blocking transmission of malaria from mosquitoes to humans by breaking the lifecycle of the malaria parasite as well as a vaccine against Plasmodium vivax Plasmodium vi·vax
A protozoan that is the most common malarial parasite of humans, causing vivax malaria. , the less severe but more widespread malaria type.
The Nairobi conference kicked off on Sunday and will close on Friday.
|Printer friendly Cite/link Email Feedback|
|Publication:||AFP Global Edition|
|Date:||Nov 3, 2009|
|Previous Article:||Poor nations 'face booming breast cancer threat'|
|Next Article:||Pakistan train collision 'kills 12'|
|WHO backs indoor DDT use for malaria.|
|New guidance on global malaria elimination released.|